Infosys Public Services to Set up Testing Center of Excellence and Consolidate IT Services for Prime Therapeutics LLC
Rockville, Maryland – March 27, 2014: Infosys Public Services, Inc., a US based subsidiary of Infosys, today announced that it has been selected by Prime Therapeutics LLC (Prime Therapeutics), a leading pharmacy benefit manager (PBM), to set up a testing center of excellence (COE) and consolidate the delivery of its application testing services as part of a new three-year contract.
Prime Therapeutics will streamline and optimize its quality assurance (QA) and testing services as well as enhance its competitiveness with Infosys Public Services’ expertise and world-class delivery model. Prime Therapeutics also expects to expand the capabilities of its QA organization and gain efficiencies in managing a large scale QA department.
“We look forward to bringing our deep experience in the health care industry and pharmacy benefit management in particular as well as globally benchmarked QA and testing service delivery to Prime Therapeutics,” said Eric Paternoster, President and CEO, Infosys Public Services, Inc. “This agreement will allow us to help the company sharpen its focus on providing better care and services to their members.”
- Prime Therapeutics selected Infosys Public Services for its health care and pharmacy benefit management expertise, proven experience with QA and testing COEs, and service delivery capabilities.
- As part of the contract, Infosys Public Services will consolidate and standardize Prime Therapeutics’ QA and testing services, currently provided by multiple service providers.
- Infosys Public Services will support Prime Therapeutics’ QA organization as they deliver across all lines of the business and increase the agility of the QA department.
- Prime Therapeutics will be able to improve application and service quality, and reduce IT costs with Infosys Public Services’ range of QA and testing frameworks, techniques, tools and accelerators.
“The rapidly evolving health care industry demands faster response and improved information technology quality to ensure Prime Therapeutics’ competitiveness,” said Jim Graham, Vice President Application Development, Prime Therapeutics. “Transforming our testing and QA services will help us achieve that and better meet the needs of health plans, employers, and government programs.”
About Infosys Public Services, Inc.
Infosys Public Services, a U.S. based subsidiary of Infosys (NYSE:INFY), is a leader in business consulting and technology solutions. We partner with healthcare and public sector organizations to help them stay ahead of the innovation curve. Our solutions, combined with execution excellence and proven best practices, allow clients to optimize their operations today while building tomorrow’s enterprise. Visit www.infosyspublicservices.com to learn more.
Infosys is a global leader in consulting, technology and outsourcing solutions. We enable clients, in more than 30 countries, to stay a step ahead of emerging business trends and outperform the competition. We help them transform and thrive in a changing world by co-creating breakthrough solutions that combine strategic insights and execution excellence. Visit www.infosys.com to see how Infosys (NYSE: INFY), with $7.4B in annual revenues and 158,000+ employees, is Building Tomorrow's Enterprise® today.
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2013 and on Form 6-K for the quarter ended December 31, 2013.These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company unless it is required by law.